Other languages Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Delayed London S.E. Other stock markets 04:07:26 29/04/2024 pm IST			5-day change	1st Jan Change
1.595 ^GBX	-3.33%		-1.24%	-30.65%

25/04	Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/02	Hemogenyx Pharmaceuticals raises money for leukaemia treatment	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	25/04
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	29/02
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	29/02
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	16/02
Hemogenyx shares rise on potential for CBR to treat brain diseases	16/02
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	16/02
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	14/02
Hemogenyx says CBR can be used intranasally to treat viral infections	14/02
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	09/02
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	09/02
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	09/02
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	02/02
Hemogenyx hails US patent application progress	02/02
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	02/02
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	16/01
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application	16/01
Hemogenyx Pharmaceuticals completes process qualification run	08/01
Hemogenyx Pharmaceuticals Wraps Up HEMO-CAR-T Process Qualification Run Following Clinical Hold	08/01
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells	08/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Other languages

Filters